Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer: A Guidelines and Case-Based Discussion - Washington, D.C. (2019)

Washington, DC US
December 3, 2019

Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).

Join Course Directors, Michael  S. Cookson, MD, MMHC and David F. Jarrard, MD, on Tuesday, December 3 at SUO Annual Meeting for an educational initiative in metastatic and castration resistant prostate cancer.


Designed for residents, fellows and APPs as well as urologists and other health care providers who care for patients with prostate cancer, this interactive live forum will focus on the application of knowledge with case studies and small group discussion integrated throughout the day. A flipped classroom approach will be utilized.  Register early to receive the Prework Library which will be available to all registered participants in July 2019.  Participants will be expected to complete the Prework Library in advance of attending the live course - complete the prework on your own time, at your convenience.  Then, come prepared on December 3 to actively engage with peers as you apply what you've learned.

The AUA in partnership with the Society of Urologic Oncology (SUO) is proud to offer this course as complimentary to the Urology community. 

Though complimentary, pre-registration is required and space is limited.

Needs assessment  findings show strong support for continued development of courses and educational materials specifically targeted at residents and fellows that cover the medical management of advanced prostate cancer.


The Live Forum will cover the following topics:

  • Identification of High Risk Disease and Initial Management of Biochemical Recurrence
  • Chemo-hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer
  • Imaging of Advanced Prostate Cancer
  • M0 CRPC: Emerging Treatment Options
  • Genetic Testing in Advanced Prostate Cancer
  • Setting Up and Managing Advanced Prostate Cancer in the Community Setting
  • Manipulating the Androgen Axis:  Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents
  • Radionuclide Therapy and Bone Health
  • Role of Chemotherapy, Treatment Sequencing and Future Approaches

*Visit the program for full details.


Acknowledgements

This educational series is supported by independent educational grants from:

  • AbbVie
  • Astellas and Pfizer, Inc.
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals Inc.
  • Genomic Health
  • Merck
  • Sanofi Genzyme

Target Audience

  • Residents
  • Fellows
  • Advanced practice providers
  • This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer

Learning Objectives

At the conclusion of this activity, participants will be able to:  

PRACTICE GAP #1 (DISEASE STATE)

  1. Describe the natural course of advanced prostate cancer from non-metastatic (M0) to metastatic hormone-sensitive disease (mHSPC), with progression to the development of castration-resistant disease (CRPC).
  2. Describe the treatment options and outcomes for patients with biochemical recurrence after failed local therapy.
  3. Identify available imaging and indications for use  including next generation PET imaging in the assessment of men with biochemical recurrence after failed local therapy.
  4. Describe the treatment options and outcomes for newly diagnosed mHSPC.
  5. Explain the implications of CRPC on the management of both M0 and M1.
  6. Discuss the molecular mechanisms and characterization of CRPC.
  7. Discuss the incorporation of genetic testing into the management of men with high risk, metastatic prostate cancer and CRPC.

PRACTICE GAP #2 (GUIDELINES)

  1. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
  2. Define M0 CRPC and the treatment options.
  3. Discuss clinically meaningful endpoints in clinical trials of patients with MO CRPC.
  4. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
  5. Discuss challenges in incorporating AUA Guidelines and management of advanced mHSPC and CRPC into community practice.

PRACTICE GAP #3 (ANDROGEN AXIS)

  1. Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
  2. Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
  3. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
  4. Discuss new uses for androgen axis agents in M0 CRPC.

PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY AND CO-MORBIDITY)

  1. Identify approved chemotherapeutics and immunotherapy for mCRPC.
  2. Describe indications and contraindications for chemotherapy and immunotherapy in patients with mCRPC.
  3. Identify co-morbid states and recognize their impact on treatment options for mCRPC.
  4. Discuss treatment sequencing.

PRACTICE GAP #5 (BONE HEALTH AND RADIONUCLIDE THERAPY)

  1. Integrate advances in bone health management into patient-specific care plans.
  2. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
  3. Discuss known adverse events associated with androgen biosynthesis inhibitors and radionuclide therapy.

PRACTICE GAP #6 (PAIN MANAGEMENT AND PALLIATIVE CARE)

  1. Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
  2. Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.
Course summary
Available credit: 
  • 5.75 AMA PRA Category 1 Credit™
  • 5.75 Non-Physician Participation
Course opens: 
05/28/2019
Course expires: 
12/03/2022
Event starts: 
12/03/2019 - 12:20pm
Event ends: 
12/03/2019 - 4:00pm
Rating: 
0

Tuesday, December 3, 2019

7:30 – 8:20 a.m.

Registation/Continental Breakfast

8:20 – 8:25 a.m.

Welcome

Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

8:25 – 8:35 a.m.

Pre–Test

Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

Session I

8:35 – 8:55 a.m.

Identification of High Risk Disease and Initial Management of Biochemical Recurrence

Steve Boorjian, MD

8:55 – 9:15 a.m.

Case–based Panel Discussions: Chemo–hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer

Case 1: High Volume M1HSPC

Case 2: Low Volume M1HSPC and Primary Management

Moderators: David Jarrard, MD & Joshua M. Lang, MD, MS

9:15 – 9:30 a.m.

Imaging of Advanced Prostate Cancer

Leonard Gomella, MD

9:30 – 9:50 a.m.

M0 CRPC: Emerging Treatment Options

Michael S. Cookson, MD, MMHC

9:50 – 10:05 a.m.

Break

10:05 – 10:35 a.m.

Genetic Testing in Advanced Prostate Cancer

Leonard Gomella, MD

10:35 – 10:55

Setting Up and Managing Advanced Prostate Cancer in the Community Setting: Unique Challenges

Benjamin Lowentritt, MD

10:55 – 11:45 a.m.

Case–based Roundtable Discussions

  • Oligometastic M1 HSPC
  • High Risk Patient (Genetic Testing)
  • MO CRPC – Index Patient 1

Moderators: Michael S. Cookson, MD MMHC & Joshua M. Lang, MD, MS

Roundtable Discussants: All Facutly

11:45 – 1:00 p.m.

A Non–CME Lunch Symposium supported by Astellas Pharma US, Inc.

Elevate Care in Prostate Cancer: Identifying Castration-Resistant Disease

Neal Shore, MD, FACS

Session II

1:00 – 1:20 p.m.

Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents

David F. Jarrard, MD

1:20 – 1:40 p.m.

Radionuclide Therapy and Bone Health

Steve Boorjian, MD

1:40 – 2:10 p.m.

Case–based Roundtable Discussions

  • M1 CRPC – CRPC Index Patient 2
  • M1 HSPC then progresses to M1 CRPC – CRPC Index Patient 3

Moderators: Steve Boorjian, MD & Evan Yu, MD

Roundtable Discussants: All Faculty

2:10 – 2:30 p.m.

Break

Session III

2:30 – 3:00 p.m.

Role of Chemotherapy, Treatment Sequencing and Future Approaches

Evan Yu, MD

3:00 – 4:00 p.m.

Case–based Roundtable Discussions

  • mCRPC Index Patient 5
  • mCRPC Index Patient 3
  • mCRPC (Index) Immunotherapy
  • mCRPC (ARV7 Variants) Future directions PARP INH

Moderators: Joshua M. Lang, MD, MS & Evan Yu, MD

Roubtable Discussants: All Faculty

Renaissance Washington D.C. Downtown
999 9th Street N.W.
Washington, DC 20001
United States
+1 (202) 898-9000

The AUA recommends that you register for the course BEFORE making travel arrangements. Once the meeting capacity is reached, the AUA is unable to guarantee a spot in the course.


General Session: Mt. Vernon Ballroom

Group Rate: $254 single/double occupancy. Reservations can be made no later than Friday, November 8, 2019 by visiting https://book.passkey.com/go/SUO19 or calling 1-800-393-2505.  Please reference “SUO/Society of Urologic Oncology” when making your reservation to receive the special group rate. 

Cut-off Date: Friday, November 8, 2019. Once the AUA/SUO group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.

Education Council Disclosures

PDF iconEducation Council Disclosures

 

AUA Office of Education Staff has nothing to disclose.

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this live activity for a maximum of 5.75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.

  • Limit content to evidence with no recommendations

  • Introduction of a debate format with an unbiased moderator (point-counterpoint)

  • Inclusion of moderated panel discussion

  • Publication of a parallel or rebuttal article for an article that is felt to be biased

  • Limit equipment representatives to providing logistics and operation support only in procedural demonstration.

  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Available Credit

  • 5.75 AMA PRA Category 1 Credit™
  • 5.75 Non-Physician Participation

Accreditation Period

Course opens: 
05/28/2019
Course expires: 
12/03/2022
Please login or register to take this course.

Registration for this course is complimentary. However, should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contacting education@auanet.org.


Cancellation Policy

AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before October 22, 2019. If AUA Education & Research cancels this course, notification will be sent by October 29, 2019.


Attendee Information & Policies

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

 

Consent to Use of Photographic Images

Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

 

Audio, Video, Photographic Equipment

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

 

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

 

Special Assistance/Dietary Needs

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.